Navigation Links
Avandia Attorney Says Study Based on 'Useless Trick Science'

Today's announcement hurts thousands of Avandia patients, counsel says

HOUSTON, June 5 /PRNewswire/ -- Noted Houston trial lawyer Mark Lanier of The Lanier Law Firm says "useless trick science" is the basis for a new study being unveiled today in New Orleans by drug maker GlaxoSmithKline (NYSE: GSK) about the side effects caused by the company's diabetes medication Avandia, which reportedly has been linked to heart problems in thousands of patients.

Mr. Lanier represents many former Avandia users who suffered heart attacks and other heart problems after taking the drug. The study released today follows six years of research paid for by GlaxoSmithKline to purportedly determine whether Avandia causes heart problems at a higher rate than other diabetes medications. The study results are being presented at the American Diabetes Association's 69th Scientific Sessions, the world's largest diabetes conference.

Among the many problems cited by medical professionals who have reviewed the study's methodology is that not enough participants were included to produce statistically valid results. The study also used Avandia in combination with other drugs rather than determining the effects of taking the drug alone.

"This study is a prime example of getting what you pay for," says Mr. Lanier. "For six years, GlaxoSmithKline has been pouring money into this study to get the results they wanted, and that's exactly what's happening today."

The Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes, or RECORD, study is based on information from diabetes patients who live in Europe. The study results follow a 2007 report in The New England Journal of Medicine, which revealed that Avandia users suffered a 43 percent increase in heart attacks and a 64 percent increase in cardiac deaths.

The U.S. Food and Drug Administration responded by requiring GlaxoSmithKline to include an updated "Black Box" warning on Avandia prescriptions about the potential increased risk of heart attacks. "Black Box" warnings are the most serious warnings required by the FDA, and are used only when a drug presents a significant risk of serious adverse side effects.

Preliminary results from the RECORD study showed no statistically significant difference in heart problems among users of Avandia and other diabetes medications, but Mr. Lanier and others who have reviewed the methodology say the results are unreliable.

"One of the FDA's own researchers said two years ago that he didn't think this study should have been conducted because it couldn't produce scientifically reliable or valid results," says Mr. Lanier. "By using tricks as science and publishing this study, GlaxoSmithKline is disregarding the safety of thousands of diabetes patients in the company's pursuit of the almighty dollar."

With offices in Los Angeles, Palo Alto, Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions in courtrooms across the country. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, intellectual property, business litigation, product liability, toxic exposure and maritime law.

For more information on Avandia, please visit The Lanier Law Firm Web site at To interview Mr. Lanier, please contact Bruce Vincent at 800-559-4534 or

SOURCE The Lanier Law Firm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Halting Avandia Use Hikes Blood Sugar Levels
2. LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects
3. Avandias Heart Risk Higher Than Others in Its Class
4. Public Citizen Petitions FDA to Ban Diabetes Drug Avandia, According to Avandia Plaintiffs Attorney Group
5. Consumer Group Seeks FDA Ban on Avandia
6. LegalView Re-Launches its Avandia Information Portal with News of the Type 2 Diabetes Drug's Risks and Dangers
7. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
8. Avandia May Slow Atherosclerosis After Bypass Surgery
9. Older Diabetics Using Avandia Face Increased Death Risk
10. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
11. Diabetes Drug Avandia Could Weaken Bones
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: